ArticleBrain and behavior2025
Exosomes miR-369-3p Alleviates Early Brain Injury After Subarachnoid Hemorrhage by Promoting Ferroptosis of M1 Microglia via Inhibiting iNOS/GPX4 Axis.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Serum miR-369-3p Downregulation Correlates with Poor Prognosis in Acute Ischemic Stroke and Mitigates Endothelial Injury by Targeting VAV3.Neurochemical research · 2026Article
- Exosomes miR-369-3p Alleviates Early Brain Injury After Subarachnoid Hemorrhage by Promoting Ferroptosis of M1 Microglia via Inhibiting iNOS/GPX4 Axis.Brain and behavior · 2025Article
- Decoding ferroptosis in intracerebral hemorrhage: multidimensional monitoring and integrative perspectives beyond single biomarkers.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundFerroptosis in pathophysiological mechanisms in early brain injury after subarachnoid hemorrhage (SAH-EBI) has been demonstrated. MicroRNAs (miRNAs) are involved in various aspects of neurological disorders. A growing number of studies suggest that intense inflammation mediated by M1 microglia after subarachnoid hemorrhage (SAH) may lead to neurological damage. According to our research and related reports, exosomal miR-369-3p is involved in the pathophysiological process of SAH, and miR-369-3p has a potentially central role in regulating inflammatory responses. Therefore, targeted delivery of miR-369-3p across the blood-brain barrier (BBB) into the brain to alleviate SAH-EBI is a promising therapeutic approach.
methodsIn this study, we extracted exosomes from RBCs and then modified RVG peptide onto the exosome surface using the click chemistry principle. Finally, miR-369-3p mimic was loaded into the RVG peptide-modified exosomes to form RVG-Exo/miR-369-3p (RVG-Exo/miR) by electroporation. Tail vein injection of RVG-Exo/miR was used to achieve delivery of miR-369-3p into the brain of SAH mice. The effect of miR-369-3p on SAH-EBI was examined by neurobehavioral scores, brain water content, Fluoro-Jade C (FJC) staining, and Nissl staining. MDA and GSH kits were used to assess the extent of ferroptosis occurrence. Western blotting analysis, immunofluorescence staining, and qRT-PCR were used to detect the levels of each protein, mRNA, and miRNA.
resultsThe exosome system (RVG-Exo/miR) successfully delivered miR-369-3p to the mouse central nervous system across the blood-brain barrierBBB. This exosomal system reduced the number of M1 microglia by enhancing their sensitivity to ferroptosis by inhibiting the expression of iNOS and GPX4. In addition, miR-369-3p treatment alleviated neurobehavioral disorders, brain edema, and neuronal damage after SAH-EBI.
conclusionsRVG-Exo/miR promotes ferroptosis in M1 microglia by inhibiting the iNOS/GPX4 axis, which may be a new and effective therapeutic strategy for treating SAH-EBI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.